Lord, Abbett & Co
GBT

Lord, Abbett & Co’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Lord, Abbett & Co’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-66,702
Closed -$2.63M – 924
2017
Q4 		$2.63M Sell
66,702
-68,809
-51% -$2.57M 0.01% 825
2017
Q3 		$4.21M Sell
135,511
-384,111
-74% -$10.8M 0.01% 789
2017
Q2 		$14.2M Sell
519,622
-20,322
-4% -$605K 0.04% 534
2017
Q1 		$19.9M Buy
+539,944
New +$13.6M 0.06% 440
2015
Q4 		– Sell
-161,577
Closed -$6.81M – 970
2015
Q3 		$6.81M Buy
+161,577
New +$7.62M 0.02% 672

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Lord, Abbett & Co's GBT Position: Q1 2018 in Review

Lord, Abbett & Co sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2018, closing a stake of 66,702 shares — an estimated $2.63M sold.

Lord, Abbett & Co first reported a position in GBT in Q3 2015 and held it in 5 quarters. The position peaked at $19.9M in Q1 2017. 176 funds tracked by Wall St. Rank hold GBT as of Q1 2018.

  • Lord, Abbett & Co reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 66,702 Global Blood Therapeutics, Inc. shares in Q1 2018, an estimated $2.63M.
  • Lord, Abbett & Co first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 5 quarters.
  • Lord, Abbett & Co's Global Blood Therapeutics, Inc. position peaked at $19.9M in Q1 2017.
  • 176 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2018.

Based on Lord, Abbett & Co's 13F filing for Q1 2018, filed 15 May 2018.